Results 41 to 50 of about 27,891 (313)

Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation

Frontiers in Endocrinology, 2021
Despite the benefits of early and effective glycemic control in the management of type 2 diabetes (T2D), achieving glycated hemoglobin (HbA1c) targets is challenging in some patients. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide effective
Juris J. Meier
doaj   +1 more source

Incident ischaemic stroke and Type 2 diabetes:trends in incidence and case fatality in Scotland 2004-2013 [PDF]

, 2017
Aim: To describe trends in first ischaemic stroke incidence and case fatality in adults with and without a diagnosis of Type 2 diabetes prior to their ischaemic stroke event in Scotland between 2004 and 2013.
Anwar, Brown, Chen, Go, Gouni-Berthold, Gregg, Guthrie, Hotchkiss, Howard, Kautzky-Willer, Kernan, Krishnamurthi, Logue, Looker, Marso, Mulnier, Paul, Peters, Peters, Read, Regensteiner, Rossi, Shah, Turner, Vamos, Wannamethee, Winston, Zhao   +27 more
core   +3 more sources

Diabeedi ravi ja kardiovaskulaarne risk [PDF]

, 2016
Eesti Arst 2016; 95(10):667 ...
Roosimaa, Mart
core   +2 more sources

The maintenance of long-term weight loss after semaglutide withdrawal in obese women with PCOS treated with metformin: a 2-year observational study

Frontiers in Endocrinology
BackgroundWithdrawal of semaglutide is frequently followed by weight regain due to compensatory biological changes that prevent the maintenance of long-term weight loss. There are some studies implying that metformin might attenuate weight regain.
Mojca Jensterle, Mojca Jensterle, Simona Ferjan, Simona Ferjan, Andrej Janez, Andrej Janez   +5 more
doaj   +1 more source

Oral diabetes medication monotherapy and short-term mortality in individuals with type 2 diabetes and coronary artery disease [PDF]

, 2018
Objective To determine whether sulfonylurea use, compared with non-sulfonylurea oral diabetes medication use, was associated with 2-year mortality in individuals with well-controlled diabetes and coronary artery disease (CAD). Research design and methods
Berkowitz, Seth A, Caplan, Liron, Grunwald, Gary K, Liu, Wenhui G, Maddox, Thomas M, Raghavan, Sridharan, Reusch, Jane E.B, Saxon, David R   +7 more
core   +3 more sources

The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission

JCI Insight, 2023
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the treatment of alcohol use disorder (AUD).
Vicky Chuong, Mehdi Farokhnia, Sophia Khom, Claire L. Pince, Sophie K. Elvig, Roman Vlkolinsky, Renata C.N. Marchette, George F. Koob, Marisa Roberto, Leandro F. Vendruscolo, Lorenzo Leggio   +10 more
doaj   +1 more source

Glucagon-Like Peptide-1 Receptor Agonist Semaglutide Improves Eating Behavior and Glycemic Control in Japanese Obese Type 2 Diabetic Patients

Metabolites, 2022
We evaluated time-course changes and the relationship between eating behavior and glycemic profile during the treatment of 34 obese type 2 diabetic patients with the glucagon-like peptide-1 receptor agonist (GLP1-RA) semaglutide.
Takayuki Masaki, Yoshinori Ozeki, Yuichi Yoshida, Mitsuhiro Okamoto, Shotaro Miyamoto, Koro Gotoh, Hirotaka Shibata   +6 more
doaj   +1 more source

The craze with semaglutide

Asian Journal of Medical Sciences
Semaglutide (Ozempic acid) belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists. These medications mimic the action of a hormone called GLP-1, which helps regulate blood glucose and promotes weight loss. One role of GLP-1 is to prompt the body to produce more insulin, which reduces blood sugar (glucose). Because of this,
Ruby Dhar, Arun Kumar, Subhradip Karmakar   +2 more
openaire   +2 more sources

ESVM Guideline on peripheral arterial disease [PDF]

, 2019
International ...
, , , Belch, Jill, Boc, Vinko, Brodmann, Marianne, Bulvas, Miroslav, Canning, Caitriona, Carpentier, Patrick H., Chraim, Ali, Colgan, Mary-Paula, Dimakakos, Evangelos, Dorigo, Walter, Frank, Ulrich, Gottsäter, Anders, Heiss, Christian, Houston, Graeme, Kahan, Thomas, Lawall, Holger, Lindstedt, Isak, Madaric, Juraj, Mahe, Guillaume, Martini, Romeo, Mazzolai, Lucia, Nikol, Sigrid, Olinic, Dan Mircea, Pernod, Giles, Poredoš, Pavel, Przywara, Stanislaw, Pécsvárady, Zsolt, Quéré, Isabelle, Righini, Marc, Roztocil, Karel, Schlager, Oliver, Stanek, Agata, Terlecki, Piotr, Vasic, Dragan, Visonà, Adriana, Wautrecht, Jean-Claude   +38 more
core   +5 more sources

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.

New England Journal of Medicine, 2020
BACKGROUND Nonalcoholic steatohepatitis (NASH) is a common disease that is associated with increased morbidity and mortality, but treatment options are limited.
P. Newsome, Kristine Buchholtz, K. Cusi, Martin Linder, T. Okanoue, V. Ratziu, A. Sanyal, A. Sejling, S. Harrison   +8 more
semanticscholar   +1 more source